Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Research programme: gene therapies - Voyager Therapeutics

Next Previous
Drug Profile

Research programme: gene therapies - Voyager Therapeutics

Alternative Names: AAV Frataxin; AAV-delivered gene therapies for CNS disorders - Voyager Therapeutics; AAVrh.10-vectored PHF1; ALS SOD1; Amyotrophic lateral sclerosis gene therapy - Voyager Therapeutics; CNS-Directed GBA1 Gene Therapy - Voyager Therapeutics; Friedreich’s ataxia gene therapy - Voyager Therapeutics; GBA1 gene replacement therapy - Voyager Therapeutics; Tau silencing gene therapy - Voyager Therapeutics; VY FXN01; VY SMN101; VY SOD101; VY SOD102; VY-NAV01

Latest Information Update: 05 Mar 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Voyager Therapeutics
  • Class Analgesics; Antidementias; Gene therapies; Neuroprotectants; Small interfering RNA
  • Mechanism of Action Gene transference; Nav1.7 voltage-gated sodium channel inhibitors; Tau protein expression inhibitors; Tau protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Huntington's disease
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Alzheimer's disease; Amyotrophic lateral sclerosis; CNS disorders; Friedreich's ataxia
  • No development reported Dementia; Huntington's disease; Pain; Spinal muscular atrophy

Most Recent Events

  • 05 Mar 2024 Voyager Therapeutics plans a phase I trial for Amyotrophic lateral sclerosis (Parenteral)
  • 28 Feb 2024 Voyager anticipates an IND filing for Amyotrophic lateral sclerosis in mid of 2025
  • 23 Feb 2024 Preclinical development is ongoing USA
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top